Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia · Delayed Price · Currency is AUD | Market Cap | 462.93M -32.6% |
| Revenue (ttm) | 101.15M +6.5% |
| Net Income | 33.92M -6.2% |
| EPS | 0.68 -5.3% |
| Shares Out | 50.43M |
| PE Ratio | 13.50 |
| Forward PE | 12.14 |
| Dividend | 0.05 (0.48%) |
| Ex-Dividend Date | Sep 4, 2025 |
| Volume | 477,084 |
| Open | 10.50 |
| Previous Close | 10.52 |
| Day's Range | 8.57 - 10.85 |
| 52-Week Range | 8.35 - 14.00 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 19.63 (+150.98%) |
| Earnings Date | Aug 27, 2026 |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a... [Read more]
Financial Performance
In fiscal year 2026, Clinuvel Pharmaceuticals's revenue was 94.02 million, a decrease of -1.05% compared to the previous year's 95.02 million. Earnings were 33.92 million, a decrease of -6.24%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CUV stock is "Buy." The 12-month stock price target is $19.63, which is an increase of 150.98% from the latest price.
News
Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2026
Delivered a 10th consecutive year of profit, with revenue surpassing AUD 100 million and strong margins. Announced plans to delist from ASX and list on Nasdaq, focusing on U.S. growth and expanding R&D in vitiligo and peptide platforms. Cash reserves rose to AUD 252 million.
Clinuvel Pharmaceuticals Annual report: H2 2026
Clinuvel Pharmaceuticals has published its H2 2026 annual report on August 27, 2026.
Clinuvel Pharmaceuticals Earnings release: H2 2026
Clinuvel Pharmaceuticals released its H2 2026 earnings on August 27, 2026, summarizing the period's financial results.
Clinuvel Pharmaceuticals Slides: H2 2026
Clinuvel Pharmaceuticals has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 27, 2026.
A decade of profitability provides foundation for CLINUVEL's U.S. expansion
CLINUVEL PHARMACEUTICALS LTD announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026).
Clinuvel To Cut 10%-20% Of Workforce Amid Relocation Of Operations To US In 2027
(RTTNews) - Clinuvel Pharmaceuticals Limited (CUV.AX), a pharmaceutical company, on Thursday announced a strategic reorganisation within the company effective from January 1, 2027, that includes a rel...
CLINUVEL implements strategic reorganisation to refocus on U.S. markets
MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce, ...
CLINUVEL's ADS to commence trading on Nasdaq
MELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that its American Depositary Share (ADS) is expected to commence trading on the Nasdaq...
Clinuvel Receives Compliance To Market SCENESSE In Canada For Treating Phototoxicity
(RTTNews) - Clinuvel Pharmaceuticals Limited (CUV.AX), a biopharmaceutical company, on Monday reported receiving a Notice of Compliance (NOC) from Health Canada for the drug SCENESSE for treating phot...
SCENESSE® approved for EPP in Canada
Health Canada NOC enables treatment for porphyria, metabolic disorder Health Canada NOC enables treatment for porphyria, metabolic disorder
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central photographic review and validated disease as...
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL's innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeti...
Clinuvel Pharmaceuticals Earnings Call Transcript: H1 2026
Revenue grew 4% year-over-year to a record high, with profitability maintained despite a 22% rise in expenses driven by R&D and expansion. Cash reserves reached AUD 233 million, supporting self-funded growth and upcoming catalysts like clinical trial readouts and Nasdaq listing.
Clinuvel Pharmaceuticals Quarterly report: H1 2026
Clinuvel Pharmaceuticals has published its H1 2026 quarterly earnings report on February 26, 2026.
Clinuvel Pharmaceuticals Slides: H1 2026
Clinuvel Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
Clinuvel Pharmaceuticals Earnings release: H1 2026
Clinuvel Pharmaceuticals released its H1 2026 earnings on February 26, 2026, summarizing the period's financial results.
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery plat...
Clinuvel Pharmaceuticals Slides: Investor Presentation
Clinuvel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2025.
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Next generation sustained-release formulations for a variety of peptides Next generation sustained-release formulations for a variety of peptides
Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2025
Reported ninth consecutive annual profit with 10% revenue growth to $105M and a 34% net margin. Cash reserves rose 22%, supporting robust R&D and expansion, while the EPP and vitiligo markets continue to grow. Major clinical and regulatory milestones are expected in the coming year.
Clinuvel Pharmaceuticals Annual report: H2 2025
Clinuvel Pharmaceuticals has published its H2 2025 annual report on August 28, 2025.
Clinuvel Pharmaceuticals Slides: H2 2025
Clinuvel Pharmaceuticals has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 28, 2025.
Clinuvel Pharmaceuticals Earnings release: H2 2025
Clinuvel Pharmaceuticals released its H2 2025 earnings on August 28, 2025, summarizing the period's financial results.
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL's primary listing on the ASX will remai...
Clinuvel Pharmaceuticals Slides: Investor Presentation
Clinuvel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2025.